Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention Trial

Details

• Personal Author:
  Cespedes D ; Darke AK ; Donaldson GW ; Ganz PA ; Johnson CR ; Meyskens FL ; Moinpour CM ; Patrick DL ; Shumaker SA ; Thompson IM Jr ; Ware JE Jr.
• Description:
  Background: The Prostate Cancer Prevention Trial (PCPT)-a randomized placebo-controlled study of the efficacy of finasteride in preventing prostate cancer-offered the opportunity to prospectively study effects of finasteride and other covariates on the health-related quality of life of participants in a multiyear trial. Methods: We assessed three health-related quality-of-life domains (measured with the Health Survey Short Form-36: Physical Functioning, Mental Health, and Vitality scales) via questionnaires completed by PCPT participants at enrollment (3 months before randomization), at 6 months after randomization, and annually for 7 years. Covariate data obtained at enrollment from patient-completed questionnaires were included in our model. Mixed-effects model analyses and a cross-sectional presentation at three time points began at 6 months after randomization. All statistical tests were two-sided. Results: For the physical function outcome (n = 16 077), neither the finasteride main effect nor the finasteride interaction with time were statistically significant. The effects of finasteride on physical function were minor and accounted for less than a 1-point difference over time in Physical Functioning scores (mixed-effect estimate = 0.07, 95% confidence interval [CI] = -0.28 to 0.42, P = .71). Comorbidities such as congestive heart failure (estimate = -5.64, 95% CI = -7.96 to -3.32, P < .001), leg pain (estimate = -2.57, 95% CI = -3.04 to -2.10, P < .001), and diabetes (estimate = -1.31, 95% CI = -2.04 to -0.57, P < .001) had statistically significant negative effects on physical function, as did current smoking (estimate = -2.34, 95% CI = -2.97 to -1.71, P < .001) and time on study (estimate = -1.20, 95% CI = -1.36 to -1.03, P < .001). Finasteride did not have a statistically significant effect on the other two dependent variables, mental health and vitality, either in the mixed-effects analyses or in the cross-sectional analysis at any of the three time points. Conclusion: Finasteride did not negatively affect SF-36 Physical Functioning, Mental Health, or Vitality scores. [Description provided by NIOSH]
• Subjects:
  Drug Therapy Men Mental Health Nervous System Occupational Health Safety
• Keywords:
  Drug Therapy Mental Health Physical Fitness Prostate Cancer Quality Of Life
• ISSN:
  0027-8874
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Journal Article
• Place as Subject:
  California ; Maryland ; Massachusetts ; North Carolina ; OSHA Region 1 ; OSHA Region 10 ; OSHA Region 3 ; OSHA Region 4 ; OSHA Region 6 ; OSHA Region 8 ; OSHA Region 9 ; Texas ; Utah ; Washington
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  104
• Issue:
  18
• NIOSHTIC Number:
  nn:20056976
• Citation:
  J Natl Cancer Inst 2012 Sep; 104(18):1373-1385
• Contact Point Address:
  Carol M. Moinpour, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, M3-C102, 1100 Fairview Ave North, PO Box 19024, Seattle, WA 98109-1024
• Email:
  cmoinpou@fhcrc.org
• Federal Fiscal Year:
  2012
• Performing Organization:
  University of Washington
• Peer Reviewed:
  True
• Start Date:
  20050701
• Source Full Name:
  Journal of the National Cancer Institute
• End Date:
  20250630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:1dfe2421adc4f0981677471ed3a602e7736477eda22b980805c9d4addca99fc825eacf6746e0c8d38d330d3de5fa55b529f780306ecb99b58bdcb98b9e111675
• Download URL:
  https://stacks.cdc.gov/view/cdc/214463/cdc_214463_DS1.pdf
• File Type:
  [PDF - 273.40 KB ]